

# Jacques Simard

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/912325/publications.pdf>

Version: 2024-02-01

348  
papers

28,075  
citations

8172

76  
h-index

7944

149  
g-index

362  
all docs

362  
docs citations

362  
times ranked

24379  
citing authors

#	ARTICLE	IF	CITATIONS
1	Risks of Breast, Ovarian, and Contralateral Breast Cancer for <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 2402.	3.8	1,898
2	Association analysis identifies 65 new breast cancer risk loci. <i>Nature</i> , 2017, 551, 92-94.	13.7	1,099
3	Large-scale genotyping identifies 41 new loci associated with breast cancer risk. <i>Nature Genetics</i> , 2013, 45, 353-361.	9.4	960
4	Breast Cancer Risk Genes Association Analysis in More than 113,000 Women. <i>New England Journal of Medicine</i> , 2021, 384, 428-439.	13.9	532
5	Pathology of Breast and Ovarian Cancers among <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers: Results from the Consortium of Investigators of Modifiers of <i>BRCA1/2</i> (CIMBA). <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 134-147.	1.1	513
6	Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. <i>Nature Genetics</i> , 2015, 47, 373-380.	9.4	513
7	A candidate prostate cancer susceptibility gene at chromosome 17p. <i>Nature Genetics</i> , 2001, 27, 172-180.	9.4	504
8	Molecular Biology of the 3 $\beta$ -Hydroxysteroid Dehydrogenase/5 $\alpha$ -Isomerase Gene Family. <i>Endocrine Reviews</i> , 2005, 26, 525-582.	8.9	502
9	Endocrine and Intracrine Sources of Androgens in Women: Inhibition of Breast Cancer and Other Roles of Androgens and Their Precursor Dehydroepiandrosterone. <i>Endocrine Reviews</i> , 2003, 24, 152-182.	8.9	500
10	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. <i>Nature Genetics</i> , 2013, 45, 371-384.	9.4	493
11	The key role of 17 $\beta$ -hydroxysteroid dehydrogenases in sex steroid biology. <i>Steroids</i> , 1997, 62, 148-158.	0.8	448
12	Prediction of Breast Cancer Risk Based on Profiling With Common Genetic Variants. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	3.0	428
13	BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors. <i>Genetics in Medicine</i> , 2019, 21, 1708-1718.	1.1	415
14	Association of Type and Location of <i>BRCA1</i> and <i>BRCA2</i> Mutations With Risk of Breast and Ovarian Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1347.	3.8	390
15	Genome-wide association studies identify four ER negative-specific breast cancer risk loci. <i>Nature Genetics</i> , 2013, 45, 392-398.	9.4	374
16	Large-scale genomic analyses link reproductive aging to hypothalamic signaling, breast cancer susceptibility and <i>BRCA1</i> -mediated DNA repair. <i>Nature Genetics</i> , 2015, 47, 1294-1303.	9.4	357
17	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. <i>Nature Genetics</i> , 2017, 49, 680-691.	9.4	356
18	Structure and Expression of a New Complementary DNA Encoding the almost Exclusive 3 $\beta$ -Hydroxysteroid Dehydrogenase/5 $\alpha$ -Isomerase in Human Adrenals and Gonads. <i>Molecular Endocrinology</i> , 1991, 5, 1147-1157.	3.7	340

#	ARTICLE	IF	CITATIONS
19	DHEA and the Intracrine Formation of Androgens and Estrogens in Peripheral Target Tissues: Its Role during Aging. <i>Steroids</i> , 1998, 63, 322-328.	0.8	335
20	BRCA2 germline mutations in male breast cancer cases and breast cancer families. <i>Nature Genetics</i> , 1996, 13, 123-125.	9.4	315
21	A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. <i>Nature Genetics</i> , 2010, 42, 885-892.	9.4	309
22	DHEA and Its Transformation into Androgens and Estrogens in Peripheral Target Tissues: Intracrinology. <i>Frontiers in Neuroendocrinology</i> , 2001, 22, 185-212.	2.5	307
23	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. <i>Nature Genetics</i> , 2017, 49, 1767-1778.	9.4	289
24	Characterization of cDNAs for Human Estradiol 17 $\beta$ -Dehydrogenase and Assignment of the Gene to Chromosome 17: Evidence of two mRNA Species with Distinct 5' Termini in Human Placenta. <i>Molecular Endocrinology</i> , 1989, 3, 1301-1309.	3.7	282
25	The OncoArray Consortium: A Network for Understanding the Genetic Architecture of Common Cancers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 126-135.	1.1	278
26	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. <i>Nature Genetics</i> , 2020, 52, 572-581.	9.4	265
27	Common Breast Cancer-Predisposition Alleles Are Associated with Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. <i>American Journal of Human Genetics</i> , 2008, 82, 937-948.	2.6	257
28	The emergence of an ethical duty to disclose genetic research results: international perspectives. <i>European Journal of Human Genetics</i> , 2006, 14, 1170-1178.	1.4	254
29	Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk. <i>PLoS Genetics</i> , 2013, 9, e1003212.	1.5	244
30	DHEA and Peripheral Androgen and Estrogen Formation: Intracrinology. <i>Annals of the New York Academy of Sciences</i> , 1995, 774, 16-28.	1.8	243
31	Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	242
32	Congenital adrenal hyperplasia due to point mutations in the type II 3 $\beta$ -hydroxysteroid dehydrogenase gene. <i>Nature Genetics</i> , 1992, 1, 239-245.	9.4	228
33	Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. <i>Human Mutation</i> , 2018, 39, 593-620.	1.1	224
34	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. <i>Nature Genetics</i> , 2015, 47, 164-171.	9.4	221
35	RAD51 135G $\rightarrow$ C Modifies Breast Cancer Risk among BRCA2 Mutation Carriers: Results from a Combined Analysis of 19 Studies. <i>American Journal of Human Genetics</i> , 2007, 81, 1186-1200.	2.6	217
36	Functional Variants at the 11q13 Risk Locus for Breast Cancer Regulate Cyclin D1 Expression through Long-Range Enhancers. <i>American Journal of Human Genetics</i> , 2013, 92, 489-503.	2.6	201

#	ARTICLE	IF	CITATIONS
37	Effect of Chest X-Rays on the Risk of Breast Cancer Among BRCA1/2 Mutation Carriers in the International BRCA1/2 Carrier Cohort Study: A Report from the EMBRACE, GENEPSO, GEO-HEBON, and IBCCS Collaboratorsâ€™ Group. <i>Journal of Clinical Oncology</i> , 2006, 24, 3361-3366.	0.8	188
38	A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer. <i>Nature Genetics</i> , 2018, 50, 968-978.	9.4	184
39	Structure of Two in Tandem Human 17 $\beta$ -Hydroxysteroid Dehydrogenase Genes. <i>Molecular Endocrinology</i> , 1990, 4, 268-275.	3.7	183
40	Personalized early detection and prevention of breast cancer: ENVISION consensus statement. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 687-705.	12.5	178
41	<i>PALB2</i>, <i>CHEK2</i> and <i>ATM</i> rare variants and cancer risk: data from COGS. <i>Journal of Medical Genetics</i> , 2016, 53, 800-811.	1.5	174
42	Common Breast Cancer Susceptibility Alleles and the Risk of Breast Cancer for <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers: Implications for Risk Prediction. <i>Cancer Research</i> , 2010, 70, 9742-9754.	0.4	169
43	A <sc>RAD</sc> 51 assay feasible in routine tumor samples calls <sc>PARP</sc> inhibitor response beyond <sc>BRCA</sc> mutation. <i>EMBO Molecular Medicine</i> , 2018, 10, .	3.3	169
44	EM-652 (SCH 57068), a third generation SERM acting as pure antiestrogen in the mammary gland and endometrium. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 1999, 69, 51-84.	1.2	157
45	Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. <i>Cancer Discovery</i> , 2016, 6, 1052-1067.	7.7	157
46	Prediction of Breast and Prostate Cancer Risks in Male <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers Using Polygenic Risk Scores. <i>Journal of Clinical Oncology</i> , 2017, 35, 2240-2250.	0.8	152
47	Gonadotropin-Releasing Hormone Agonists in the Treatment of Prostate Cancer. <i>Endocrine Reviews</i> , 2005, 26, 361-379.	8.9	149
48	Tamoxifen and Risk of Contralateral Breast Cancer for <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. <i>Journal of Clinical Oncology</i> , 2013, 31, 3091-3099.	0.8	148
49	(S)-(+)-4-[7-(2,2-Dimethyl-1-oxopro-poxy)-4-methyl-2-[4-[2-(1-piperidinyl)-ethoxy]phenyl]-2H-1-benzopyran-3-yl]- phenyl 2,2-Dimethylpropanoate (EM-800):Â A Highly Potent, Specific, and Orally Active Nonsteroidal Antiestrogen. <i>Journal of Medicinal Chemistry</i> , 1997, 40, 2117-2122.	2.9	143
50	A Combined Genomewide Linkage Scan of 1,233 Families for Prostate Cancerâ€™Susceptibility Genes Conducted by the International Consortium for Prostate Cancer Genetics. <i>American Journal of Human Genetics</i> , 2005, 77, 219-229.	2.6	138
51	Reproductive and Hormonal Factors, and Ovarian Cancer Risk for <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers: Results from the International <i>BRCA1/2</i> Carrier Cohort Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 601-610.	1.1	130
52	Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. <i>Nature Genetics</i> , 2016, 48, 374-386.	9.4	125
53	Role of 17 $\beta$ -Hydroxysteroid Dehydrogenases in Sex Steroid Formation in Peripheral Intracrine Tissues. <i>Trends in Endocrinology and Metabolism</i> , 2000, 11, 421-427.	3.1	124
54	Linkage Analysis of Chromosome 1q Markers in 136 Prostate Cancer Families. <i>American Journal of Human Genetics</i> , 1998, 62, 653-658.	2.6	123

#	ARTICLE	IF	CITATIONS
55	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. <i>Nature Genetics</i> , 2020, 52, 56-73.	9.4	120
56	Genetically Predicted Body Mass Index and Breast Cancer Risk: Mendelian Randomization Analyses of Data from 145,000 Women of European Descent. <i>PLoS Medicine</i> , 2016, 13, e1002105.	3.9	118
57	Regulation of Progesterone-Binding Breast Cyst Protein GCDFP-24 Secretion by Estrogens and Androgens in Human Breast Cancer Cells: A New Marker of Steroid Action in Breast Cancer*. <i>Endocrinology</i> , 1990, 126, 3223-3231.	1.4	110
58	Stimulation of Growth Hormone Release and Synthesis by Estrogens in Rat Anterior Pituitary Cells in Culture. <i>Endocrinology</i> , 1986, 119, 2004-2011.	1.4	105
59	Identification of a BRCA2-Specific Modifier Locus at 6p24 Related to Breast Cancer Risk. <i>PLoS Genetics</i> , 2013, 9, e1003173.	1.5	105
60	Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation. <i>Nature Communications</i> , 2014, 5, 4999.	5.8	105
61	Down-Regulation of Estrogen Receptors by Androgens in the ZR-75-1 Human Breast Cancer Cell Line*. <i>Endocrinology</i> , 1989, 125, 392-399.	1.4	102
62	Regulation of Pro-Gonadotropin-Releasing Hormone Gene Expression by Sex Steroids in The Brain of Male and Female Rats. <i>Molecular Endocrinology</i> , 1989, 3, 1748-1756.	3.7	99
63	Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. <i>Human Molecular Genetics</i> , 2009, 18, 4442-4456.	1.4	99
64	Height and Breast Cancer Risk: Evidence From Prospective Studies and Mendelian Randomization. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv219.	3.0	99
65	Genetic discrimination and life insurance: a systematic review of the evidence. <i>BMC Medicine</i> , 2013, 11, 25.	2.3	98
66	Fine-Scale Mapping of the FGFR2 Breast Cancer Risk Locus: Putative Functional Variants Differentially Bind FOXA1 and E2F1. <i>American Journal of Human Genetics</i> , 2013, 93, 1046-1060.	2.6	98
67	Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. <i>Nature Communications</i> , 2016, 7, 11375.	5.8	93
68	STRUCTURE AND SEXUAL DIMORPHIC EXPRESSION OF A LIVER-SPECIFIC RAT 3 $\beta$ -HYDROXYSTEROID DEHYDROGENASE/ISOMERASE. <i>Endocrinology</i> , 1990, 127, 3237-3239.	1.4	92
69	Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. <i>Nature Communications</i> , 2019, 10, 1741.	5.8	90
70	New Insight into the Molecular Basis of 3 $\beta$ -Hydroxysteroid Dehydrogenase Deficiency: Identification of Eight Mutations in the HSD3B2 Gene in Eleven Patients from Seven New Families and Comparison of the Functional Properties of Twenty-Five Mutant Enzymes1. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999, 84, 4410-4425.	1.8	88
71	Shared heritability and functional enrichment across six solid cancers. <i>Nature Communications</i> , 2019, 10, 431.	5.8	88
72	European polygenic risk score for prediction of breast cancer shows similar performance in Asian women. <i>Nature Communications</i> , 2020, 11, 3833.	5.8	88

#	ARTICLE	IF	CITATIONS
73	Combination therapy for prostate cancer. Endocrine and biologic basis of its choice as new standard first-line therapy. <i>Cancer</i> , 1993, 71, 1059-1067.	2.0	86
74	Stimulation of Androgen-Dependent Gene Expression by the Adrenal Precursors Dehydroepiandrosterone and Androstenedione in the Rat Ventral Prostate*. <i>Endocrinology</i> , 1989, 124, 2745-2754.	1.4	85
75	The Tumor Suppressor PALB2: Inside Out. <i>Trends in Biochemical Sciences</i> , 2019, 44, 226-240.	3.7	83
76	GATA Factors and the Nuclear Receptors, Steroidogenic Factor 1/Liver Receptor Homolog 1, Are Key Mutual Partners in the Regulation of the Human 3 $\beta$ -Hydroxysteroid Dehydrogenase Type 2 Promoter. <i>Molecular Endocrinology</i> , 2005, 19, 2358-2370.	3.7	82
77	Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. <i>Genetics in Medicine</i> , 2020, 22, 1653-1666.	1.1	82
78	Molecular cloning, cDNA structure and predicted amino acid sequence of bovine 3 $\beta$ -hydroxy-5-ene steroid dehydrogenase/5 $\alpha$ -reductase. <i>FEBS Letters</i> , 1989, 259, 153-157.	1.3	81
79	Associations of obesity and circulating insulin and glucose with breast cancer risk: a Mendelian randomization analysis. <i>International Journal of Epidemiology</i> , 2019, 48, 795-806.	0.9	81
80	Association of Specific LDL Receptor Gene Mutations With Differential Plasma Lipoprotein Response to Simvastatin in Young French Canadians With Heterozygous Familial Hypercholesterolemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1998, 18, 1007-1012.	1.1	80
81	Incorporating truncating variants in PALB2, CHEK2, and ATM into the BOADICEA breast cancer risk model. <i>Genetics in Medicine</i> , 2016, 18, 1190-1198.	1.1	80
82	Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers. <i>Breast Cancer Research</i> , 2012, 14, R33.	2.2	78
83	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. <i>Nature Communications</i> , 2016, 7, 12675.	5.8	78
84	BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv315.	3.0	77
85	Fine-Scale Mapping of the 5q11.2 Breast Cancer Locus Reveals at Least Three Independent Risk Variants Regulating MAP3K1. <i>American Journal of Human Genetics</i> , 2015, 96, 5-20.	2.6	76
86	BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families. <i>Breast Cancer Research</i> , 2005, 8, R3.	2.2	75
87	Assessment of polygenic architecture and risk prediction based on common variants across fourteen cancers. <i>Nature Communications</i> , 2020, 11, 3353.	5.8	75
88	Evaluation of BRCA1 and BRCA2 mutation prevalence, risk prediction models and a multistep testing approach in French-Canadian families with high risk of breast and ovarian cancer. <i>Journal of Medical Genetics</i> , 2006, 44, 107-121.	1.5	72
89	Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. <i>Breast Cancer Research</i> , 2011, 13, R110.	2.2	71
90	Molecular basis of human 3 $\beta$ -hydroxysteroid dehydrogenase deficiency. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 1995, 53, 127-138.	1.2	70

#	ARTICLE	IF	CITATIONS
91	Structure-function relationships of 3 $\beta$ -hydroxysteroid dehydrogenase: Contribution made by the molecular genetics of 3 $\beta$ -hydroxysteroid dehydrogenase deficiency. <i>Steroids</i> , 1997, 62, 176-184.	0.8	68
92	Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. <i>Human Molecular Genetics</i> , 2011, 20, 3304-3321.	1.4	68
93	Induction of 3 $\beta$ -Hydroxysteroid Dehydrogenase/ $\beta$ 5- $\beta$ 4 Isomerase Type 1 Gene Transcription in Human Breast Cancer Cell Lines and in Normal Mammary Epithelial Cells by Interleukin-4 and Interleukin-13. <i>Molecular Endocrinology</i> , 1999, 13, 66-81.	3.7	67
94	Multiple novel prostate cancer susceptibility signals identified by fine-mapping of known risk loci among Europeans. <i>Human Molecular Genetics</i> , 2015, 24, 5589-5602.	1.4	67
95	Localization of 3 $\beta$ -Hydroxysteroid Dehydrogenase/ $\beta$ 5- $\beta$ 4 Isomerase in Rat Gonads and Adrenal Glands by Immunocytochemistry and <i>in Situ</i> Hybridization. <i>Endocrinology</i> , 1990, 127, 1394-1403.	1.4	66
96	11 Structure, regulation and role of 3 $\beta$ -hydroxysteroid dehydrogenase, 17 $\beta$ -hydroxysteroid dehydrogenase and aromatase enzymes in the formation of sex steroids in classical and peripheral intracrine tissues. <i>Bailliere's Clinical Endocrinology and Metabolism</i> , 1994, 8, 451-474.	1.0	66
97	The Human Type II 17 $\beta$ -Hydroxysteroid Dehydrogenase Gene Encodes Two Alternatively Spliced mRNA Species. <i>DNA and Cell Biology</i> , 1995, 14, 849-861.	0.9	65
98	Characterization of macaque 3 $\beta$ -hydroxy-5-ene steroid dehydrogenase/ $\beta$ 5- $\beta$ 4 isomerase: structure and expression in steroidogenic and peripheral tissues in primate. <i>Molecular and Cellular Endocrinology</i> , 1991, 75, 101-110.	1.6	63
99	Genetic mapping of the breast-ovarian cancer syndrome to a small interval on chromosome 17q12-21: exclusion of candidate genes EDH17B2 and RARA. <i>Human Molecular Genetics</i> , 1993, 2, 1193-1199.	1.4	63
100	Characterization of the effects of the novel non-steroidal antiestrogen EM-800 on basal and estrogen-induced proliferation of T-47D, ZR-75-1 and MCF-7 human breast cancer cells <i>in vitro</i> . , 1997, 73, 104-112.		63
101	Inhibitory Effect of Estrogens on GCDFP-15 mRNA Levels and Secretion in ZR-75-1 Human Breast Cancer Cells. <i>Molecular Endocrinology</i> , 1989, 3, 694-702.	3.7	61
102	Congenital Adrenal Hyperplasia due to 3 $\beta$ -Hydroxysteroid Dehydrogenase/ $\beta$ 5- $\beta$ 4 Isomerase Deficiency. <i>Seminars in Reproductive Medicine</i> , 2002, 20, 255-276.	0.5	59
103	Evidence that the 5p12 Variant rs10941679 Confers Susceptibility to Estrogen-Receptor-Positive Breast Cancer through FGF10 and MRPS30 Regulation. <i>American Journal of Human Genetics</i> , 2016, 99, 903-911.	2.6	59
104	Personalized Risk Assessment for Prevention and Early Detection of Breast Cancer: Integration and Implementation (PERSPECTIVE I&M). <i>Journal of Personalized Medicine</i> , 2021, 11, 511.	1.1	59
105	Regulation of 3 $\beta$ -Hydroxysteroid Dehydrogenase/ $\beta$ 5- $\beta$ 4 Isomerase Expression and Activity in the Hypophysectomized Rat Ovary: Interactions between the Stimulatory Effect of Human Chorionic Gonadotropin and the Luteolytic Effect of Prolactin*. <i>Endocrinology</i> , 1990, 127, 2726-2737.	1.4	58
106	Induction of 3 $\beta$ -Hydroxysteroid Dehydrogenase/ Isomerase Type 1 Expression by Interleukin-4 in Human Normal Prostate Epithelial Cells, Immortalized Keratinocytes, Colon, and Cervix Cancer Cell Lines <sup>1</sup> . <i>Endocrinology</i> , 1999, 140, 4573-4584.	1.4	57
107	Pooled genome linkage scan of aggressive prostate cancer: results from the International Consortium for Prostate Cancer Genetics. <i>Human Genetics</i> , 2006, 120, 471-485.	1.8	57
108	Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. <i>Breast Cancer Research</i> , 2014, 16, 3416.	2.2	57

#	ARTICLE	IF	CITATIONS
109	Novel Associations between Common Breast Cancer Susceptibility Variants and Risk-Predicting Mammographic Density Measures. <i>Cancer Research</i> , 2015, 75, 2457-2467.	0.4	55
110	A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. <i>Cancer Research</i> , 2018, 78, 5419-5430.	0.4	54
111	Interleukin-4 and interleukin-13 inhibit estrogen-induced breast cancer cell proliferation and stimulate GCDFP-15 expression in human breast cancer cells. <i>Molecular and Cellular Endocrinology</i> , 1996, 121, 11-18.	1.6	53
112	Common non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association Consortium. <i>Human Molecular Genetics</i> , 2014, 23, 6096-6111.	1.4	53
113	Prediction of breast cancer risk based on common genetic variants in women of East Asian ancestry. <i>Breast Cancer Research</i> , 2016, 18, 124.	2.2	52
114	Genome-wide association study of germline variants and breast cancer-specific mortality. <i>British Journal of Cancer</i> , 2019, 120, 647-657.	2.9	52
115	Molecular and genealogical characterization of the R1443X BRCA1 mutation in high-risk French-Canadian breast/ovarian cancer families. <i>Human Genetics</i> , 2005, 117, 119-132.	1.8	51
116	Fine-scale mapping of 8q24 locus identifies multiple independent risk variants for breast cancer. <i>International Journal of Cancer</i> , 2016, 139, 1303-1317.	2.3	51
117	Perspective: Prostate Cancer Susceptibility Genes. <i>Endocrinology</i> , 2002, 143, 2029-2040.	1.4	49
118	MicroRNA Related Polymorphisms and Breast Cancer Risk. <i>PLoS ONE</i> , 2014, 9, e109973.	1.1	49
119	Factors Associated with an Individual's Decision to Withdraw from Genetic Testing for Breast And Ovarian Cancer Susceptibility: Implications for Counseling. <i>Genetic Testing and Molecular Biomarkers</i> , 2007, 11, 45-54.	1.7	48
120	Characterization of the Cancer Spectrum in Men With Germline <i>BRCA1</i> and <i>BRCA2</i> Pathogenic Variants. <i>JAMA Oncology</i> , 2020, 6, 1218.	3.4	48
121	Are ATM Mutations 7271T→G and IVS10-6T→G Really High-Risk Breast Cancer-Susceptibility Alleles?. <i>Cancer Research</i> , 2004, 64, 840-843.	0.4	47
122	Common Variants at the 19p13.1 and <i>ZNF365</i> Loci Are Associated with ER Subtypes of Breast Cancer and Ovarian Cancer Risk in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 645-657.	1.1	47
123	DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. <i>PLoS Genetics</i> , 2014, 10, e1004256.	1.5	47
124	EM-652 (SCH57068), a pure SERM having complete antiestrogenic activity in the mammary gland and endometrium. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2001, 79, 213-225.	1.2	46
125	No Evidence of False Reassurance among Women with an Inconclusive <i>BRCA1/2</i> Genetic Test Result. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005, 14, 2862-2867.	1.1	46
126	Identification of novel breast cancer susceptibility loci in meta-analyses conducted among Asian and European descendants. <i>Nature Communications</i> , 2020, 11, 1217.	5.8	46



#	ARTICLE	IF	CITATIONS
127	Mutation analysis and characterization of ATR sequence variants in breast cancer cases from high-risk French Canadian breast/ovarian cancer families. <i>BMC Cancer</i> , 2006, 6, 230.	1.1	45
128	No Evidence of BRCA1/2 Genomic Rearrangements in High-Risk French-Canadian Breast/Ovarian Cancer Families. <i>Genetic Testing and Molecular Biomarkers</i> , 2006, 10, 104-115.	1.7	45
129	Personalized medicine and access to health care: potential for inequitable access?. <i>European Journal of Human Genetics</i> , 2013, 21, 143-147.	1.4	45
130	Functional analysis of genetic variants in the high-risk breast cancer susceptibility gene PALB2. <i>Nature Communications</i> , 2019, 10, 5296.	5.8	45
131	Generation of a Transcription Map at the HSD17B Locus Centromeric to BRCA1 at 17q21. <i>Genomics</i> , 1995, 28, 530-542.	1.3	44
132	Multihormonal Control of Pre-Pro-Somatostatin mRNA Levels in the Periventricular Nucleus of the Male and Female Rat Hypothalamus. <i>Neuroendocrinology</i> , 1990, 52, 527-536.	1.2	43
133	Genetic predisposition to ductal carcinoma in situ of the breast. <i>Breast Cancer Research</i> , 2016, 18, 22.	2.2	43
134	Prospective evaluation of a breast-cancer risk model integrating classical risk factors and polygenic risk in 15 cohorts from six countries. <i>International Journal of Epidemiology</i> , 2022, 50, 1897-1911.	0.9	43
135	Localization of the Endogenous Benzodiazepine Ligand Octadecaneuropeptide in the Rat Testis. <i>Endocrinology</i> , 1990, 127, 1986-1994.	1.4	42
136	Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women. <i>Breast Cancer Research</i> , 2016, 18, 112.	2.2	42
137	Crucial role of cytokines in sex steroid formation in normal and tumoral tissues. <i>Molecular and Cellular Endocrinology</i> , 2001, 171, 25-40.	1.6	41
138	Results of a genome-wide linkage analysis in prostate cancer families ascertained through the ACTANE consortium. <i>Prostate</i> , 2003, 57, 270-279.	1.2	41
139	Life insurance: genomic stratification and risk classification. <i>European Journal of Human Genetics</i> , 2014, 22, 575-579.	1.4	41
140	A Mendelian randomization analysis of circulating lipid traits and breast cancer risk. <i>International Journal of Epidemiology</i> , 2020, 49, 1117-1131.	0.9	41
141	Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers. <i>Breast Cancer Research</i> , 2020, 22, 8.	2.2	41
142	Genetic Variation at 9p22.2 and Ovarian Cancer Risk for BRCA1 and BRCA2 Mutation Carriers. <i>Journal of the National Cancer Institute</i> , 2011, 103, 105-116.	3.0	40
143	Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2. <i>Human Molecular Genetics</i> , 2015, 24, 2966-2984.	1.4	40
144	Functional characterization of 84 PALB2 variants of uncertain significance. <i>Genetics in Medicine</i> , 2020, 22, 622-632.	1.1	40

#	ARTICLE	IF	CITATIONS
145	Congenital adrenal hyperplasia caused by a novel homozygous frameshift mutation 2731 <sup>AA</sup> in type II 3 <sup>β</sup> -hydroxysteroid dehydrogenase gene (HSD3B2) in three male patients of Afghan/Pakistani origin. <i>Human Molecular Genetics</i> , 1994, 3, 327-330.	1.4	39
146	Inverse relationships between cell proliferation and basal or androgen-stimulated apolipoprotein D secretion in LNCaP human prostate cancer cells. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 1994, 51, 167-174.	1.2	39
147	Interleukin-6 inhibits the potent stimulatory action of androgens, glucocorticoids and interleukin-1 $\beta$ on apolipoprotein D and GCDFP-15 expression in human breast cancer cells. <i>International Journal of Cancer</i> , 1995, 62, 732-737.	2.3	39
148	Comparison of in vitro effects of the pure antiandrogens OH-flutamide, casodex, and nilutamide on androgen-sensitive parameters. <i>Urology</i> , 1997, 49, 580-589.	0.5	39
149	A Novel A10E Homozygous Mutation in the <i>HSD3B2</i> Gene Causing Severe Salt-Wasting 3 <sup>β</sup> -Hydroxysteroid Dehydrogenase Deficiency in 46,XX and 46,XY French-Canadians: Evaluation of Gonadal Function after Puberty <sup>1</sup> . <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 1968-1974.	1.8	39
150	Genetic Predisposition to In Situ and Invasive Lobular Carcinoma of the Breast. <i>PLoS Genetics</i> , 2014, 10, e1004285.	1.5	39
151	Association of Genomic Domains in <i>BRCA1</i> and <i>BRCA2</i> with Prostate Cancer Risk and Aggressiveness. <i>Cancer Research</i> , 2020, 80, 624-638.	0.4	39
152	A global functional analysis of missense mutations reveals two major hotspots in the PALB2 tumor suppressor. <i>Nucleic Acids Research</i> , 2019, 47, 10662-10677.	6.5	39
153	Full oestrogenic activity of C19- <sup>5</sup> adrenal steroids in rat pituitary lactotrophs and somatotrophs. <i>Molecular and Cellular Endocrinology</i> , 1988, 55, 233-242.	1.6	38
154	Potent stimulatory effect of interleukin-1 $\beta$ on apolipoprotein D and gross cystic disease fluid protein-15 expression in human breast-cancer cells. <i>International Journal of Cancer</i> , 1994, 59, 400-407.	2.3	38
155	Local and Systemic Reduction by Topical Finasteride or Flutamide of Hamster Flank Organ Size and Enzyme Activity. <i>Journal of Investigative Dermatology</i> , 1995, 105, 678-682.	0.3	38
156	Clinical Management Recommendations for Surveillance and Risk-Reduction Strategies for Hereditary Breast and Ovarian Cancer Among Individuals Carrying a Deleterious BRCA1 or BRCA2 Mutation. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2007, 29, 45-60.	0.3	38
157	Identification and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer risk. <i>Human Molecular Genetics</i> , 2015, 24, 285-298.	1.4	38
158	Inhibitory Effect of Androgen on Estrogen-Induced Prolactin Messenger Ribonucleic Acid Accumulation in the Male Rat Anterior Pituitary Gland. <i>Endocrinology</i> , 1989, 125, 1821-1828.	1.4	37
159	Rapid modulation of ovarian 3 <sup>β</sup> -hydroxysteroid dehydrogenase/ <sup>5</sup> - <sup>4</sup> isomerase gene expression by prolactin and human chorionic gonadotropin in the hypophysectomized rat. <i>Molecular and Cellular Endocrinology</i> , 1994, 99, 63-71.	1.6	37
160	Synergistic Action of Prolactin (PRL) and Androgen on PRL-Inducible Protein Gene Expression in Human Breast Cancer Cells: A Unique Model for Functional Cooperation between Signal Transducer and Activator of Transcription-5 and Androgen Receptor. <i>Molecular Endocrinology</i> , 2002, 16, 1696-1710.	3.7	37
161	Mutational analysis of the breast cancer susceptibility gene BRIP1 /BACH1/FANCF in high-risk non-BRCA1/BRCA2 breast cancer families. <i>Journal of Human Genetics</i> , 2008, 53, 579-591.	1.1	37
162	Association of the Variants <i>CASP8</i> D302H and <i>CASP10</i> V410I with Breast and Ovarian Cancer Risk in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 2859-2868.	1.1	37

#	ARTICLE	IF	CITATIONS
163	Polymorphisms in a Putative Enhancer at the 10q21.2 Breast Cancer Risk Locus Regulate NRBF2 Expression. <i>American Journal of Human Genetics</i> , 2015, 97, 22-34.	2.6	37
164	Effect of Luteinizing Hormone Releasing Hormone (LHRH) and [d-Trp6, Des-Gly-NH210]LHRH Ethylamide on $\hat{\alpha}$ -Subunit and LH $\hat{\beta}$ Messenger Ribonucleic Acid Levels in Rat Anterior Pituitary Cells in Culture. <i>Molecular Endocrinology</i> , 1988, 2, 521-527.	3.7	36
165	Functional characterization of the novel L108W and P186L mutations detected in the type II 3 $\hat{\beta}$ -hydroxysteroid dehydrogenase gene of a male pseudohermaphrodite with congenital adrenal hyperplasia. <i>Human Molecular Genetics</i> , 1994, 3, 1639-1645.	1.4	36
166	Generation of an Integrated Transcription Map of the BRCA2 Region on Chromosome 13q12-q13. <i>Genomics</i> , 1996, 36, 86-99.	1.3	36
167	COMPLEXO: identifying the missing heritability of breast cancer via next generation collaboration. <i>Breast Cancer Research</i> , 2013, 15, 402.	2.2	36
168	Regulation of Growth Hormone mRNA and Pro-Opiomelanocortin mRNA Levels by Cyclic AMP in Rat Anterior Pituitary Cells in Culture. <i>DNA and Cell Biology</i> , 1986, 5, 263-270.	5.1	35
169	Health Behaviors and Psychological Distress in Women Initiating BRCA1/2 Genetic Testing: Comparison with Control Population. <i>Journal of Genetic Counseling</i> , 2008, 17, 314-326.	0.9	35
170	Genetically Predicted Levels of DNA Methylation Biomarkers and Breast Cancer Risk: Data From 228,951 Women of European Descent. <i>Journal of the National Cancer Institute</i> , 2020, 112, 295-304.	3.0	35
171	Detection of polymorphisms in the estradiol 17 $\hat{\beta}$ -hydroxysteroid dehydrogenase II gene at the EDH17B2 locus on 17q11-q21. <i>Human Molecular Genetics</i> , 1993, 2, 479-483.	1.4	34
172	Synthesis and Antiestrogenic Activity of Diaryl Thioether Derivatives. <i>Journal of Medicinal Chemistry</i> , 1994, 37, 1115-1125.	2.9	34
173	Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. <i>Human Mutation</i> , 2012, 33, 690-702.	1.1	34
174	Assessing Associations between the AURKA-HMMR-TPX2-TUBG1 Functional Module and Breast Cancer Risk in BRCA1/2 Mutation Carriers. <i>PLoS ONE</i> , 2015, 10, e0120020.	1.1	34
175	Inherited mutations in BRCA1 and BRCA2 in an unselected multiethnic cohort of Asian patients with breast cancer and healthy controls from Malaysia. <i>Journal of Medical Genetics</i> , 2018, 55, 97-103.	1.5	34
176	Personalizing Breast Cancer Screening Based on Polygenic Risk and Family History. <i>Journal of the National Cancer Institute</i> , 2021, 113, 434-442.	3.0	34
177	Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers: an international cohort study. <i>American Journal of Obstetrics and Gynecology</i> , 2021, 225, 51.e1-51.e17.	0.7	34
178	Dopaminergic regulation of pre-proNPY mRNA levels in the rat arcuate nucleus. <i>Neuroscience Letters</i> , 1991, 127, 96-98.	1.0	33
179	Detection of a novel mutation (stop 468) in exon 10 of the low-density lipoprotein receptor gene causing familial hypercholesterolemia among French Canadians. <i>Human Molecular Genetics</i> , 1994, 3, 1689-1691.	1.4	33
180	Identification and characterization of the G15D mutation found in a male patient with 3 $\beta$ -hydroxysteroid dehydrogenase (3 $\beta$ -HSD) deficiency: alteration of the putative NAD-binding domain of Type II 3 $\beta$ -HSD. <i>Biochemistry</i> , 1995, 34, 2893-2900.	1.2	33

#	ARTICLE	IF	CITATIONS
181	An intergenic risk locus containing an enhancer deletion in 2q35 modulates breast cancer risk by deregulating IGFBP5 expression. <i>Human Molecular Genetics</i> , 2016, 25, 3863-3876.	1.4	33
182	Oral Contraceptive Use and Breast Cancer Risk: Retrospective and Prospective Analyses From a BRCA1 and BRCA2 Mutation Carrier Cohort Study. <i>JNCI Cancer Spectrum</i> , 2018, 2, pky023.	1.4	33
183	Regulation of sex steroid formation by interleukin-4 and interleukin-6 in breast cancer cells. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 1998, 65, 151-162.	1.2	32
184	Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriers. <i>Human Molecular Genetics</i> , 2011, 20, 4732-4747.	1.4	32
185	Family Communication Following <i>BRCA1/2</i> Genetic Testing: A Close Look at the Process. <i>Journal of Genetic Counseling</i> , 2013, 22, 323-335.	0.9	32
186	A large-scale assessment of two-way SNP interactions in breast cancer susceptibility using 46 450 cases and 42 461 controls from the breast cancer association consortium. <i>Human Molecular Genetics</i> , 2014, 23, 1934-1946.	1.4	32
187	Transcriptome-wide association study of breast cancer risk by estrogen receptor status. <i>Genetic Epidemiology</i> , 2020, 44, 442-468.	0.6	32
188	Keoxifene shows pure antiestrogenic activity in pituitary gonadotrophs. <i>Molecular and Cellular Endocrinology</i> , 1985, 39, 141-144.	1.6	31
189	Synthetic progestins stimulate prostatic binding protein messenger RNAs in the rat ventral prostate. <i>Molecular and Cellular Endocrinology</i> , 1990, 68, 169-179.	1.6	31
190	Glucocorticoids enhance activation of the human type II 3 $\beta$ -hydroxysteroid dehydrogenase/5 $\alpha$ -reductase isomerase gene. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2002, 82, 55-63.	1.2	31
191	Association of breast cancer risk with genetic variants showing differential allelic expression: Identification of a novel breast cancer susceptibility locus at 4q21. <i>Oncotarget</i> , 2016, 7, 80140-80163.	0.8	31
192	Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. <i>Breast Cancer Research</i> , 2016, 18, 64.	2.2	31
193	Prevalence of <i>BRCA1</i> and <i>BRCA2</i> pathogenic variants in a large, unselected breast cancer cohort. <i>International Journal of Cancer</i> , 2019, 144, 1195-1204.	2.3	31
194	Linkage analysis of 26 Canadian breast and breast-ovarian cancer families. <i>Human Genetics</i> , 1995, 95, 545-50.	1.8	30
195	<i>AURKA</i> F311 Polymorphism and Breast Cancer Risk in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers: A Consortium of Investigators of Modifiers of BRCA1/2 Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2007, 16, 1416-1421.	1.1	30
196	Height and Body Mass Index as Modifiers of Breast Cancer Risk in <i>BRCA1/2</i> Mutation Carriers: A Mendelian Randomization Study. <i>Journal of the National Cancer Institute</i> , 2019, 111, 350-364.	3.0	30
197	A network analysis to identify mediators of germline-driven differences in breast cancer prognosis. <i>Nature Communications</i> , 2020, 11, 312.	5.8	30
198	Atrial natriuretic factor-induced cGMP accumulation in rat anterior pituitary cells in culture is not coupled to hormonal secretion. <i>Regulatory Peptides</i> , 1986, 15, 269-278.	1.9	29

#	ARTICLE	IF	CITATIONS
199	OVERVIEW: Modulation by Sex Steroids and [ $\text{Des-Gly-NH-}2\text{-}10\text{Luteinizing Hormone (LH)-Releasing Hormone Ethylamide of } \pm\text{-Subunit and LH}^2\text{ Messenger Ribonucleic Acid Levels in the Rat Anterior Pituitary Gland. Molecular Endocrinology, 1988, 2, 775-784.}$	3.7	29
200	Return of Research Results: General Principles and International Perspectives. <i>Journal of Law, Medicine and Ethics</i> , 2011, 39, 583-592.	0.4	28
201	Identification of New Genetic Susceptibility Loci for Breast Cancer Through Consideration of Gene-Environment Interactions. <i>Genetic Epidemiology</i> , 2014, 38, 84-93.	0.6	28
202	The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer. <i>Npj Breast Cancer</i> , 2019, 5, 38.	2.3	28
203	Women's Views on Multifactorial Breast Cancer Risk Assessment and Risk-Stratified Screening: A Population-Based Survey from Four Provinces in Canada. <i>Journal of Personalized Medicine</i> , 2021, 11, 95.	1.1	28
204	Health professionals' perspectives on breast cancer risk stratification: understanding evaluation of risk versus screening for disease. <i>Public Health Reviews</i> , 2019, 40, 2.	1.3	27
205	Polygenic risk scores for prediction of breast cancer risk in Asian populations. <i>Genetics in Medicine</i> , 2022, 24, 586-600.	1.1	27
206	Interactions between Estrogens, Androgens, Progestins, and Glucocorticoids in ZR-75-1 Human Breast Cancer Cells. <i>Annals of the New York Academy of Sciences</i> , 1990, 595, 130-148.	1.8	26
207	Mapping of the HSD17B2 gene encoding type II $17\beta$ -hydroxysteroid dehydrogenase close to D16S422 on chromosome 16q24.1-q24.2. <i>Genomics</i> , 1995, 25, 724-726.	1.3	26
208	Structure-function relationships and molecular genetics of the $3\beta$ -hydroxysteroid dehydrogenase gene family. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 1995, 55, 489-505.	1.2	26
209	Characterization of a novel mutation causing hepatic lipase deficiency among French Canadians. <i>Journal of Lipid Research</i> , 2003, 44, 1508-1514.	2.0	26
210	The AIB1 Polyglutamine Repeat Does Not Modify Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006, 15, 76-79.	1.1	26
211	Evaluation of the Contribution of the Three Breast Cancer Susceptibility Genes <i>CHEK2</i> , <i>STK11</i> , and <i>PALB2</i> in Non-BRCA1/2 French Canadian Families with High Risk of Breast Cancer. <i>Genetic Testing and Molecular Biomarkers</i> , 2010, 14, 515-526.	0.3	26
212	An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. <i>Breast Cancer Research</i> , 2015, 17, 61.	2.2	26
213	RAD51B in Familial Breast Cancer. <i>PLoS ONE</i> , 2016, 11, e0153788.	1.1	26
214	Ontogenesis of $3\beta$ -Hydroxysteroid Dehydrogenase $^5\beta$ 4 Isomerase in the Rat Adrenal as Revealed by Immunocytochemistry and <i>In Situ</i> Hybridization. <i>Endocrinology</i> , 1991, 129, 2687-2692.	1.4	25
215	Rapid restriction fragment analysis for screening four point mutations of the Low-density lipoprotein receptor gene in French Canadians. <i>Human Mutation</i> , 1995, 6, 243-246.	1.1	25
216	Identification of three mutations in the low-density lipoprotein receptor gene causing familial hypercholesterolemia among French Canadians. <i>Human Mutation</i> , 1998, 11, S226-S231.	1.1	25

#	ARTICLE	IF	CITATIONS
217	Fine-Scale Mapping of the 4q24 Locus Identifies Two Independent Loci Associated with Breast Cancer Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1680-1691.	1.1	24
218	Alcohol Consumption, Cigarette Smoking, and Risk of Breast Cancer for <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers: Results from The BRCA1 and BRCA2 Cohort Consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 368-378.	1.1	24
219	Somatostatin prevents the desensitizing action of growth hormone-releasing factor on growth hormone release. <i>Peptides</i> , 1987, 8, 199-205.	1.2	23
220	Antagonism between estrogens and androgens on <i>gcdfp-15</i> gene expression in ZR-75-1 cells and correlation between GCDFP-15 and estrogen as well as progesterone receptor expression in human breast cancer. <i>The Journal of Steroid Biochemistry</i> , 1989, 34, 397-402.	1.3	23
221	Purification, Cloning, Complementary DNA Structure, and Predicted Amino Acid Sequence of Human Estradiol 17 $\beta$ -Dehydrogenase. <i>Annals of the New York Academy of Sciences</i> , 1990, 595, 40-52.	1.8	23
222	Characterization and modulation of sex steroid metabolizing activity in normal human keratinocytes in primary culture and HaCaT cells. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2003, 87, 167-179.	1.2	23
223	A Nonsynonymous Polymorphism in <i>IRS1</i> Modifies Risk of Developing Breast and Ovarian Cancers in <i>BRCA1</i> and Ovarian Cancer in <i>BRCA2</i> Mutation Carriers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 1362-1370.	1.1	23
224	Polygenic risk modeling for prediction of epithelial ovarian cancer risk. <i>European Journal of Human Genetics</i> , 2022, 30, 349-362.	1.4	23
225	Characterization of two mRNA species encoding human estradiol 17 $\beta$ -dehydrogenase and assignment of the gene to chromosome 17. <i>The Journal of Steroid Biochemistry</i> , 1989, 34, 189-197.	1.3	22
226	Parallel solid-phase synthesis of a model library of 7 $\beta$ -alkylamide estradiol derivatives as potential estrogen receptor antagonists. <i>Bioorganic and Medicinal Chemistry Letters</i> , 1999, 9, 2827-2832.	1.0	22
227	Fine mapping of low-density lipoprotein receptor gene by genetic linkage on chromosome 19p13.1-p13.3 and study of the founder effect of four French Canadian low-density lipoprotein receptor gene mutations. <i>Atherosclerosis</i> , 1999, 143, 145-151.	0.4	22
228	Multiple Signaling Pathways Mediate Interleukin-4-Induced 3 $\beta$ -Hydroxysteroid Dehydrogenase/5 $\alpha$ -Reductase Type 1 Gene Expression in Human Breast Cancer Cells. <i>Molecular Endocrinology</i> , 2000, 14, 229-240.	3.7	22
229	Candidate Genetic Modifiers for Breast and Ovarian Cancer Risk in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 308-316.	1.1	22
230	Adrenal C19-5-ene steroids induce full estrogenic responses in rat pituitary gonadotrophs. <i>The Journal of Steroid Biochemistry</i> , 1987, 26, 539-546.	1.3	21
231	Macrophage Scavenger Receptor 1 999C>T (R293X) Mutation and Risk of Prostate Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005, 14, 397-402.	1.1	21
232	Association of genetic susceptibility variants for type 2 diabetes with breast cancer risk in women of European ancestry. <i>Cancer Causes and Control</i> , 2016, 27, 679-693.	0.8	21
233	The Influence of Number and Timing of Pregnancies on Breast Cancer Risk for Women With <i>BRCA1</i> or <i>BRCA2</i> Mutations. <i>JNCI Cancer Spectrum</i> , 2018, 2, pky078.	1.4	21
234	A New Insight Into the Molecular Basis of 3 $\beta$ -Hydroxysteroid Dehydrogenase Deficiency. <i>Endocrine Research</i> , 2000, 26, 761-770.	0.6	20

#	ARTICLE	IF	CITATIONS
235	Multiple signal transduction pathways mediate interleukin-4-induced 3 $\beta$ -hydroxysteroid dehydrogenase/17 $\alpha$ - $\beta$ isomerase in normal and tumoral target tissues. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2001, 76, 213-225.	1.2	20
236	SNP-SNP interaction analysis of NF- $\kappa$ B signaling pathway on breast cancer survival. <i>Oncotarget</i> , 2015, 6, 37979-37994.	0.8	20
237	Gene-environment interactions involving functional variants: Results from the Breast Cancer Association Consortium. <i>International Journal of Cancer</i> , 2017, 141, 1830-1840.	2.3	20
238	Multiple Factors Controlling ACTH Secretion at the Anterior Pituitary Level. <i>Annals of the New York Academy of Sciences</i> , 1987, 512, 97-114.	1.8	19
239	Localization of peripheral benzodiazepine binding sites and diazepam-binding inhibitor (DBI) mRNA in mammary glands and dimethylbenz(1 $\pm$ )anthracene (DMBA)-induced mammary tumors in the rat. <i>Regulatory Peptides</i> , 1991, 33, 263-273.	1.9	19
240	Mapping of the regulatory subunits RII $\alpha$ and RII $\beta$ of cAMP-Dependent protein kinase genes on human chromosome 7. <i>Genomics</i> , 1992, 14, 63-69.	1.3	19
241	The gene for hereditary breast-ovarian cancer, BRCA1, maps distal to EDH17B2 in chromosome region 17q12-q21. <i>Human Molecular Genetics</i> , 1994, 3, 1679-1682.	1.4	19
242	Fine scale mapping of the 17q22 breast cancer locus using dense SNPs, genotyped within the Collaborative Oncological Gene-Environment Study (COGs). <i>Scientific Reports</i> , 2016, 6, 32512.	1.6	19
243	Differential Burden of Rare and Common Variants on Tumor Characteristics, Survival, and Mode of Detection in Breast Cancer. <i>Cancer Research</i> , 2018, 78, 6329-6338.	0.4	19
244	Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers. <i>British Journal of Cancer</i> , 2019, 121, 180-192.	2.9	19
245	A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. <i>Nature Communications</i> , 2021, 12, 1078.	5.8	19
246	Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores. <i>Journal of the National Cancer Institute</i> , 2022, 114, 109-122.	3.0	19
247	Pure selective estrogen receptor modulators, new molecules having absolute cell specificity ranging from pure antiestrogenic to complete estrogen-like activities. <i>Advances in Protein Chemistry</i> , 2001, 56, 293-368.	4.4	18
248	Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. <i>Breast Cancer Research and Treatment</i> , 2017, 161, 117-134.	1.1	18
249	Molecular cloning, upstream sequence and promoter studies of the human gene for the regulatory subunit RII $\alpha$ of cAMP-dependent protein kinase. <i>Biochimica Et Biophysica Acta Gene Regulatory Mechanisms</i> , 1997, 1350, 98-108.	2.4	17
250	A focus group study on breast cancer risk presentation: one format does not fit all. <i>European Journal of Human Genetics</i> , 2013, 21, 719-724.	1.4	17
251	Breast Cancer Risk Estimation and Personal Insurance: A Qualitative Study Presenting Perspectives from Canadian Patients and Decision Makers. <i>Frontiers in Genetics</i> , 2017, 8, 128.	1.1	17
252	Genetic linkage mapping of the CYP11A1 gene encoding the cholesterol side-chain cleavage P450 $\text{sc}$ close to the CYP1A1 gene and DI 5S204 in the chromosome 15q22.33-q23 region. <i>Pharmacogenetics and Genomics</i> , 1998, 8, 49-53.	5.7	16

#	ARTICLE	IF	CITATIONS
253	Synthesis and structure-activity relationships of analogs of EM-652 (acolbifene), a pure selective estrogen receptor modulator. Study of nitrogen substitution. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2005, 20, 165-177.	2.5	16
254	Breast and ovarian cancer screening of non-carriers from BRCA1/2 mutation-positive families: 2-year follow-up of cohorts from France and Quebec. <i>European Journal of Human Genetics</i> , 2011, 19, 494-499.	1.4	16
255	The association between weight at birth and breast cancer risk revisited using Mendelian randomisation. <i>European Journal of Epidemiology</i> , 2019, 34, 591-600.	2.5	16
256	The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant. <i>Genetics in Medicine</i> , 2021, 23, 1726-1737.	1.1	16
257	Opposite effects of estrogen and the progestin R5020 on cell proliferation and GCDFP-15 expression in ZR-75-1 human breast cancer cells. <i>Molecular and Cellular Endocrinology</i> , 1990, 73, 171-178.	1.6	15
258	Life Events may Contribute to Family Communication About Cancer Risk Following BRCA1/2 Testing. <i>Journal of Genetic Counseling</i> , 2013, 22, 249-257.	0.9	15
259	Common variants in breast cancer risk loci predispose to distinct tumor subtypes. <i>Breast Cancer Research</i> , 2022, 24, 2.	2.2	15
260	Localization and Regulation of Expression of the FAR-17A Gene in the Hamster Flank Organs. <i>Journal of Investigative Dermatology</i> , 1996, 107, 44-50.	0.3	14
261	A new alternative splice variant of BRCA1 containing an additional in-frame exon. <i>Biochimica Et Biophysica Acta Gene Regulatory Mechanisms</i> , 2005, 1731, 57-65.	2.4	14
262	Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study. <i>Breast Cancer Research</i> , 2014, 16, R51.	2.2	14
263	Inherited variants in the inner centromere protein (INCENP) gene of the chromosomal passenger complex contribute to the susceptibility of ER-negative breast cancer. <i>Carcinogenesis</i> , 2015, 36, 256-271.	1.3	14
264	Re-evaluating genetic variants identified in candidate gene studies of breast cancer risk using data from nearly 280,000 women of Asian and European ancestry. <i>EBioMedicine</i> , 2019, 48, 203-211.	2.7	14
265	A response to Personalised medicine and population health: breast and ovarian cancer. <i>Human Genetics</i> , 2019, 138, 287-289.	1.8	14
266	17 $\beta$ -Hydroxylase/17,20-Lyase Deficiency Due to Novel Compound Heterozygote Mutations: Treatment for Tall Stature in a Female with Male Pseudohermaphroditism and Spontaneous Puberty in her Affected Sister. <i>Journal of Pediatric Endocrinology and Metabolism</i> , 2005, 18, 403-11.	0.4	13
267	Use of Dietary Supplements Among Women at High Risk of Hereditary Breast and Ovarian Cancer (HBOC) Tested for Cancer Susceptibility. <i>Nutrition and Cancer</i> , 2006, 54, 157-165.	0.9	13
268	Mutation analysis and characterization of HSD17B2 sequence variants in breast cancer cases from French Canadian families with high risk of breast and ovarian cancer. <i>Journal of Molecular Endocrinology</i> , 2008, 40, 161-172.	1.1	13
269	Analysis of 17 $\beta$ -hydroxysteroid dehydrogenase types 5, 7, and 12 genetic sequence variants in breast cancer cases from French Canadian Families with high risk of breast and ovarian cancer. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2009, 116, 134-153.	1.2	13
270	Exploring resources for intrafamilial communication of cancer genetic risk: we still need to talk. <i>European Journal of Human Genetics</i> , 2013, 21, 903-910.	1.4	13



#	ARTICLE	IF	CITATIONS
271	Medical Genetic Counseling for Breast Cancer in Primary Care: A Synthesis of Major Determinants of Physicians' Practices in Primary Care Settings. <i>Public Health Genomics</i> , 2014, 17, 190-208.	0.6	13
272	Evaluation of associations between genetically predicted circulating protein biomarkers and breast cancer risk. <i>International Journal of Cancer</i> , 2020, 146, 2130-2138.	2.3	13
273	PALB2 Variants: Protein Domains and Cancer Susceptibility. <i>Trends in Cancer</i> , 2021, 7, 188-197.	3.8	13
274	Detection of frequent BglII polymorphism by polymerase chain reaction and TaqI restriction fragment length polymorphism for 3 $\beta$ -hydroxysteroid dehydrogenase/5 $\beta$ - $\beta$ 4 isomerase at the human HSD $\beta$ 3 locus (1p11?p13). <i>Human Genetics</i> , 1991, 87, 753-4.	1.8	12
275	Structure of primate and rodent orthologs of the prostate cancer susceptibility gene ELAC2. <i>Biochimica Et Biophysica Acta Gene Regulatory Mechanisms</i> , 2004, 1679, 230-247.	2.4	12
276	CYP17 and breast cancer: no overall effect, but what about interactions?. <i>Breast Cancer Research</i> , 2005, 7, 238-42.	2.2	12
277	Partnering in Oncogenetic Research â€“ The INHERIT BRCA Experience: Opportunities and Challenges. <i>Familial Cancer</i> , 2006, 5, 3-13.	0.9	12
278	Genetic sequence variations and ADPRT haplotype analysis in French Canadian families with high risk of breast cancer. <i>Journal of Human Genetics</i> , 2007, 52, 963-977.	1.1	12
279	No association of TGFB1 L10P genotypes and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a multi-center cohort study. <i>Breast Cancer Research and Treatment</i> , 2009, 115, 185-192.	1.1	12
280	Genetic variation in mitotic regulatory pathway genes is associated with breast tumor grade. <i>Human Molecular Genetics</i> , 2014, 23, 6034-6046.	1.4	12
281	Fine-Mapping of the 1p11.2 Breast Cancer Susceptibility Locus. <i>PLoS ONE</i> , 2016, 11, e0160316.	1.1	12
282	Organizational challenges to equity in the delivery of services within a new personalized risk-based approach to breast cancer screening. <i>New Genetics and Society</i> , 2019, 38, 38-59.	0.7	12
283	Envisioning Implementation of a Personalized Approach in Breast Cancer Screening Programs: Stakeholder Perspectives. <i>Healthcare Policy</i> , 2019, 15, 39-54.	0.3	12
284	Characteristics of the desensitization of growth hormone and cyclic AMP responses to growth hormone-releasing factor and prostaglandin E2 in rat anterior pituitary cells in culture. <i>Molecular and Cellular Endocrinology</i> , 1986, 46, 79-89.	1.6	11
285	Assignment of the gene encoding the catalytic subunit C $\beta$ 2 of CAMP-dependent protein kinase to the p36 band on chromosome. <i>Human Genetics</i> , 1992, 88, 653-657.	1.8	11
286	Genetic Linkage Mapping of the Dehydroepiandrosterone Sulfotransferase (STD) Gene on the Chromosome 19q13.3 Region. <i>Genomics</i> , 1995, 29, 781-783.	1.3	11
287	Self-reported mammography use following BRCA1/2 genetic testing may be overestimated. <i>Familial Cancer</i> , 2012, 11, 27-32.	0.9	11
288	Effectiveness of Risk-Reducing Salpingo-Oophorectomy in Preventing Ovarian Cancer in a High-Risk French Canadian Population. <i>International Journal of Gynecological Cancer</i> , 2012, 22, 974-978.	1.2	10

#	ARTICLE	IF	CITATIONS
289	Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. <i>PLoS ONE</i> , 2016, 11, e0158801.	1.1	10
290	The knowledge value-chain of genetic counseling for breast cancer: an empirical assessment of prediction and communication processes. <i>Familial Cancer</i> , 2016, 15, 1-17.	0.9	10
291	Formation and degradation of dihydrotestosterone by recombinant members of the rat 3 $\beta$ -hydroxysteroid dehydrogenase/5 $\alpha$ - $\beta$ isomerase family. <i>Molecular and Cellular Endocrinology</i> , 1994, 103, 29-38.	1.6	9
292	Incidence and predictors of positive and negative effects of BRCA1/2 genetic testing on familial relationships: a 3-year follow-up study. <i>Genetics in Medicine</i> , 2012, 14, 60-68.	1.1	9
293	Disentangling the determinants of interest and willingness-to-pay for breast cancer susceptibility testing in the general population: a cross-sectional Web-based survey among women of Qu $\acute{e}$ bec (Canada). <i>BMJ Open</i> , 2018, 8, e016662.	0.8	9
294	Toward a Population-Based Breast Cancer Risk Stratification Approach? The Needs and Concerns of Healthcare Providers. <i>Journal of Personalized Medicine</i> , 2021, 11, 540.	1.1	9
295	Potential of polygenic risk scores for improving population estimates of women's breast cancer genetic risks. <i>Genetics in Medicine</i> , 2021, 23, 2114-2121.	1.1	9
296	Mendelian randomisation study of smoking exposure in relation to breast cancer risk. <i>British Journal of Cancer</i> , 2021, 125, 1135-1145.	2.9	9
297	PHIP - a novel candidate breast cancer susceptibility locus on 6q14.1. <i>Oncotarget</i> , 2017, 8, 102769-102782.	0.8	9
298	Opposite Effects of Prolactin and Corticosterone on the Expression and Activity of 3 $\beta$ -Hydroxysteroid Dehydrogenase/5 $\alpha$ - $\beta$ Isomerase in Rat Skin. <i>Journal of Investigative Dermatology</i> , 1994, 103, 60-64.	0.3	8
299	Localization of BRCA1 Gene Expression in Adult Cynomolgus Monkey Tissues. <i>Journal of Histochemistry and Cytochemistry</i> , 1997, 45, 1173-1188.	1.3	8
300	Changes in Health-Related Behaviours Following BRCA1/2 Genetic Testing: The Case of Hormone Replacement Therapy. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2004, 26, 1059-1066.	0.3	8
301	Analysis of GADD45A sequence variations in French Canadian families with high risk of breast cancer. <i>Journal of Human Genetics</i> , 2008, 53, 490-498.	1.1	8
302	Pooled analysis indicates that the GSTT1 deletion, GSTM1 deletion, and GSTP1 Ile105Val polymorphisms do not modify breast cancer risk in BRCA1 and BRCA2 mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2010, 122, 281-285.	1.1	8
303	Systematic mixed-methods reviews are not ready to be assessed with the available tools. <i>Journal of Clinical Epidemiology</i> , 2011, 64, 926-928.	2.4	8
304	Functional analysis of promoter variants in KU70 and their role in cancer susceptibility. <i>Genes Chromosomes and Cancer</i> , 2012, 51, 1007-1013.	1.5	8
305	Genetic variation in the immunosuppression pathway genes and breast cancer susceptibility: a pooled analysis of 42,510 cases and 40,577 controls from the Breast Cancer Association Consortium. <i>Human Genetics</i> , 2016, 135, 137-154.	1.8	8
306	A Collaborative Model to Implement Flexible, Accessible and Efficient Oncogenetic Services for Hereditary Breast and Ovarian Cancer: The C-MOnGene Study. <i>Cancers</i> , 2021, 13, 2729.	1.7	8

#	ARTICLE	IF	CITATIONS
307	Should Age-Dependent Absolute Risk Thresholds Be Used for Risk Stratification in Risk-Stratified Breast Cancer Screening?. <i>Journal of Personalized Medicine</i> , 2021, 11, 916.	1.1	8
308	Transcriptional signature of lymphoblastoid cell lines of <i>BRCA1</i> , <i>BRCA2</i> and non- <i>BRCA1/2</i> high risk breast cancer families. <i>Oncotarget</i> , 2017, 8, 78691-78712.	0.8	8
309	Potent Antagonism between Estrogens and Androgens on GCDFP-15 Expression and Cell Growth in the ZR-75-1 Human Breast Cancer Cells. <i>Annals of the New York Academy of Sciences</i> , 1990, 586, 174-187.	1.8	7
310	Characterization of HSD17B1 sequence variants in breast cancer cases from French Canadian families with high risk of breast and ovarian cancer. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2008, 109, 115-128.	1.2	7
311	Increased Use of BRCA Mutation Test in Unaffected Women Over the Period 2004–2014 in the U.S.: Further Evidence of the “Angelina Jolie Effect”. <i>American Journal of Preventive Medicine</i> , 2017, 53, e195-e196.	1.6	7
312	Evaluation of the association of heterozygous germline variants in NTHL1 with breast cancer predisposition: an international multi-center study of 47,180 subjects. <i>Npj Breast Cancer</i> , 2021, 7, 52.	2.3	7
313	Combination therapy in stage C and D prostatic cancer: rationale and five-year clinical experience. <i>Cancer and Metastasis Reviews</i> , 1987, 6, 615-636.	2.7	6
314	Effect of the Women's Health Initiative Study Publication on Hormone Replacement Therapy Use among Women Who Have Undergone <i>BRCA1/2</i> Testing. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2007, 16, 157-160.	1.1	6
315	SNP Set Association Testing for Survival Outcomes in the Presence of Intrafamilial Correlation. <i>Genetic Epidemiology</i> , 2015, 39, 406-414.	0.6	6
316	Clinical follow-up and breast and ovarian cancer screening of true <i>BRCA1/2</i> noncarriers: a qualitative investigation. <i>Genetics in Medicine</i> , 2016, 18, 627-634.	1.1	6
317	Functional Analysis of Promoter Variants in Genes Involved in Sex Steroid Action, DNA Repair and Cell Cycle Control. <i>Genes</i> , 2019, 10, 186.	1.0	6
318	Pleiotropy-guided transcriptome imputation from normal and tumor tissues identifies candidate susceptibility genes for breast and ovarian cancer. <i>Human Genetics and Genomics Advances</i> , 2021, 2, 100042.	1.0	6
319	Functional annotation of the 2q35 breast cancer risk locus implicates a structural variant in influencing activity of a long-range enhancer element. <i>American Journal of Human Genetics</i> , 2021, 108, 1190-1203.	2.6	6
320	Large-scale cross-cancer fine-mapping of the 5p15.33 region reveals multiple independent signals. <i>Human Genetics and Genomics Advances</i> , 2021, 2, 100041.	1.0	6
321	Rare germline copy number variants (CNVs) and breast cancer risk. <i>Communications Biology</i> , 2022, 5, 65.	2.0	6
322	A Genome-Wide Gene-Based Gene–Environment Interaction Study of Breast Cancer in More than 90,000 Women. <i>Cancer Research Communications</i> , 2022, 2, 211-219.	0.7	6
323	Influence of the family cluster effect on psychosocial variables in families undergoing <i>BRCA1/2</i> genetic testing for cancer susceptibility. <i>Psycho-Oncology</i> , 2012, 21, 515-523.	1.0	5
324	ABRAXAS (FAM175A) and Breast Cancer Susceptibility: No Evidence of Association in the Breast Cancer Family Registry. <i>PLoS ONE</i> , 2016, 11, e0156820.	1.1	5

#	ARTICLE	IF	CITATIONS
325	Inherited Chromosomally Integrated Human Herpesvirus 6 and Breast Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 425-427.	1.1	5
326	Do women change their breast cancer mammogram screening behaviour after BRCA1/2 testing?. <i>Familial Cancer</i> , 2017, 16, 35-40.	0.9	5
327	Two truncating variants in FANCC and breast cancer risk. <i>Scientific Reports</i> , 2019, 9, 12524.	1.6	5
328	Association of germline variation with the survival of women with BRCA1/2 pathogenic variants and breast cancer. <i>Npj Breast Cancer</i> , 2020, 6, 44.	2.3	5
329	DSNetwork: An Integrative Approach to Visualize Predictions of Variants'™ Deleteriousness. <i>Frontiers in Genetics</i> , 2019, 10, 1349.	1.1	5
330	CYP3A7*1C allele: linking premenopausal oestrone and progesterone levels with risk of hormone receptor-positive breast cancers. <i>British Journal of Cancer</i> , 2021, 124, 842-854.	2.9	5
331	Risk-Stratified Approach to Breast Cancer Screening in Canada: Women'™s Knowledge of the Legislative Context and Concerns about Discrimination from Genetic and Other Predictive Health Data. <i>Journal of Personalized Medicine</i> , 2021, 11, 726.	1.1	5
332	Genomic organization and expression of the mouse Brca2 gene. <i>Mammalian Genome</i> , 2002, 13, 352-358.	1.0	4
333	Evaluation of chromosome 6p22 as a breast cancer risk modifier locus in a follow-up study of BRCA2 mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2012, 136, 295-302.	1.1	4
334	Women'™s perceptions of PERSPECTIVE: a breast cancer risk stratification e-platform. <i>Hereditary Cancer in Clinical Practice</i> , 2022, 20, 8.	0.6	4
335	Characterization of the guinea pig 3 $\beta$ -hydroxysteroid dehydrogenase/5 $\alpha$ - $\beta$ -isomerase expressed in the adrenal gland and gonads. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2005, 97, 289-298.	1.2	3
336	Using the Impact of Event Scale to Evaluate Distress in the Context of Genetic Testing for Breast Cancer Susceptibility. <i>Psychological Reports</i> , 2006, 98, 873-881.	0.9	3
337	The CYP17A1 $\beta$ 34T>A polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2011, 126, 521-527.	1.1	3
338	Usefulness of Canadian Public Health Insurance Administrative Databases to Assess Breast and Ovarian Cancer Screening Imaging Technologies for BRCA1/2 Mutation Carriers. <i>Canadian Association of Radiologists Journal</i> , 2016, 67, 308-312.	1.1	3
339	Body mass index and the association between low-density lipoprotein cholesterol as predicted by HMGCR genetic variants and breast cancer risk. <i>International Journal of Epidemiology</i> , 2019, 48, 1727-1730.	0.9	3
340	Sequence kernel association test for survival outcomes in the presence of a non-susceptible fraction. <i>Biostatistics</i> , 2020, 21, 518-530.	0.9	3
341	HRT Use Among Women Tested for BRCA1/2 Mutations Following Publication of the Women'™s Health Initiative Study Results. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2005, 27, 321.	0.3	2
342	rs2735383, located at a microRNA binding site in the 3'UTR of NBS1, is not associated with breast cancer risk. <i>Scientific Reports</i> , 2016, 6, 36874.	1.6	2

#	ARTICLE	IF	CITATIONS
343	VEXOR: an integrative environment for prioritization of functional variants in fine-mapping analysis. <i>Bioinformatics</i> , 2017, 33, 1389-1391.	1.8	2
344	Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk. <i>Scientific Reports</i> , 2020, 10, 9688.	1.6	2
345	Uncovering the Contribution of Moderate-Penetrance Susceptibility Genes to Breast Cancer by Whole-Exome Sequencing and Targeted Enrichment Sequencing of Candidate Genes in Women of European Ancestry. <i>Cancers</i> , 2022, 14, 3363.	1.7	2
346	Authors'™ response: Associations of obesity and circulating insulin and glucose with breast cancer risk. <i>International Journal of Epidemiology</i> , 2019, 48, 1016-1017.	0.9	1
347	Gynecologic Cancer Risk and Genetics: Informing an Ideal Model of Gynecologic Cancer Prevention. <i>Current Oncology</i> , 2022, 29, 4632-4646.	0.9	1
348	BRCA1 Gene Expression in Reproductive and Endocrine Tissues in Adult Cynomolgus Monkey. <i>Annals of the New York Academy of Sciences</i> , 1998, 839, 444-446.	1.8	0